転移性がん治療薬の世界市場

転移性がん治療薬の世界市場は2030年までに1,071億米ドルに到達

2024年に756億米ドルと推定される転移性がん治療薬の世界市場は、2024～2030年の分析期間においてCAGR 6.0%で成長し、2030年には1,071億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである化学療法薬は、CAGR 7.2%を記録し、分析期間終了時には578億米ドルに達すると予測されます。ホルモン療法薬セグメントの成長率は、分析期間中CAGR 4.2%と推定されます。

米国市場は206億米ドル、中国はCAGR 9.6％で成長すると予測

米国の転移性がん治療薬市場は2024年に206億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに221億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは9.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.8%と5.9%と予測されています。欧州では、ドイツがCAGR 3.9%で成長すると予測されています。

世界の転移性がん治療薬市場- 主要動向と促進要因まとめ

転移性がんが従来の腫瘍学プロトコルを超えた独自の治療戦略を必要とするのはなぜか？

転移性がんは、悪性腫瘍が原発を越えて遠隔臓器に転移する段階であり、がんの進行の中で最も進行し、生命を脅かす段階です。転移がんは、がん関連死亡の大部分を占める、世界的に最も困難な腫瘍学の課題の1つです。転移性がんは限局性腫瘍とは異なり、複雑な遺伝的不均一性を示し、標準治療に対する抵抗性を示し、手術や放射線のような局所治療に対する反応性が低下するため、特殊な薬理学的アプローチが必要となります。

転移性がんにおける治療目標は、根治を目指すものから、生存期間の延長、QOLの維持、病勢進行の抑制に重点を置くことが多いです。そのため、この領域における薬剤開発は、細胞毒性よりも細胞増殖抑制効果、転移シグナル伝達経路の標的阻害、分子プロファイリングに基づく個別化を重視しています。転移は単なる空間的拡大ではなく、明確な生物学的状態であるという認識の高まりは、その基礎となるメカニズムや、脳、骨、肝臓などの臓器特異的転移に合わせた治療法に関する集中的な研究に拍車をかけています。

標的治療、免疫腫瘍学、ゲノム技術革新はどのように薬剤の状況を変えているのか？

転移性がんの治療法は、標的治療薬、モノクローナル抗体、免疫チェックポイント阻害剤の台頭により劇的に進化しました。トラスツズマブ（HER2+乳がん）、オシメルチニブ（EGFR変異NSCLC）、エンザルタミド（転移性前立腺がん）などの薬剤は、受容体特異的阻害が転移性環境においていかに生存期間を延長できるかを例証しています。これらの薬剤は、異常なシグナル伝達カスケードを破壊し、血管新生を阻害し、ホルモン受容体をブロックし、あるいは転移細胞の遊走や接着機構を阻害するようにデザインされています。

免疫療法、特にペムブロリズマブやニボルマブのようなPD-1/PD-L1阻害剤は、腫瘍細胞の内因性免疫認識を増強することにより、メラノーマ、NSCLC、腎細胞がんの治療成績に革命をもたらしています。CAR-T細胞療法や二重特異性抗体もまた、転移性血液腫瘍や固形腫瘍で研究されており、一次治療を回避する持続性クローンを標的としています。ゲノムシークエンシングプラットフォームとリキッドバイオプシーは、腫瘍変異のリアルタイム追跡を可能にし、患者を精密治療や複数の転移促進因子を同時に標的とする併用レジメンに適合させるのに役立ちます。

転移性腫瘍治療薬の臨床的・商業的拡大を牽引しているがん種と地域市場は？

乳がん、肺がん、大腸がん、前立腺がん、メラノーマは、転移性抗がん剤市場において商業的に最も重要ながん種であり、それぞれが相当な患者集団と差別化された治療パイプラインを有しています。例えば、HER2陽性乳がんとトリプルネガティブ乳がんでは、転移の進行パターンが異なり、対応する治療法も異なります。脳転移を伴う非小細胞肺がん（NSCLC）は、次世代ALK阻害剤とEGFR阻害剤の優先度が高い領域です。同様に、転移性結腸直腸がん（mCRC）と肝細胞がんは、VEGF、EGFR、マルチキナーゼ経路を標的とする生物学的製剤による治療が増加しています。

北米と欧州は、強固な償還構造、調査インフラ、FDAやEMAが承認した薬剤への早期アクセスに支えられ、依然として最大の収益を上げている地域です。しかし、アジア太平洋市場、特に中国、日本、韓国は、がん罹患率の増加、バイオマーカー主導型医療への投資、バイオシミラーや国産免疫療法の地域承認により、急成長を遂げています。ラテンアメリカと中東は、価格設定やインフラの格差に制約されているもの、官民パートナーシップやがん医療改革イニシアティブを通じてアクセスを拡大しています。

転移性がん治療薬市場の長期的な成長と革新の原動力は？

転移性がん治療薬市場の成長は、がん罹患率の上昇、分子診断法の拡大、新規治療薬の後期治療アルゴリズムへの戦略的再配置によって牽引されています。がん免疫学、エピジェネティクス、腫瘍微小環境調節における画期的な進歩により、治療可能な標的の範囲が拡大しています。コンパニオン診断とバイオマーカーによる治療選択は、患者の層別化を可能にし、奏効率を向上させ、後期治療における試行錯誤を最小化します。

医薬品パイプラインは、併用レジメン、シーケンス戦略、抗体薬物複合体（ADC）、PARP阻害剤、腫瘍診断薬などの新規メカニズムにますます焦点が当てられています。さらに、転移性疾患における延命治療に対する支払者の支援により、より広範な市場参入が可能になっています。リアルワールドエビデンス（RWE）、価値ベースの価格設定モデル、早期承認や画期的治療薬指定などの規制の枠組みは、商業化をさらに加速させています。

転移性がん治療が、より個別化され、生物学的情報に基づいた治療レジメンへと移行するにつれて、この死亡率の高い分野に対応する薬剤の市場は拡大し続け、治療進歩の中心的柱として、精密腫瘍学、免疫調節、トランスレーショナルリサーチの融合が明らかになるであろう。

セグメント

治療法（化学療法、ホルモン療法、標的療法、免疫療法）、適応症（乳がん、肺がん、前立腺がん、大腸がん、黒色腫、その他の適応症）、流通チャネル（病院薬局、ドラッグストア・小売薬局、オンラインプロバイダー）

調査対象企業の例（注目の32社）

• AbbVie Inc.
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• Biogen Inc.
• Bristol-Myers Squibb Company
• Celgene Corporation
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Ipsen
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi S.A.
• Seagen Inc.
• Takeda Pharmaceutical Company

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Metastatic Cancer Drugs Market to Reach US$107.1 Billion by 2030

The global market for Metastatic Cancer Drugs estimated at US$75.6 Billion in the year 2024, is expected to reach US$107.1 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Chemotherapy Drugs, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$57.8 Billion by the end of the analysis period. Growth in the Hormonal Therapy Drugs segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$20.6 Billion While China is Forecast to Grow at 9.6% CAGR

The Metastatic Cancer Drugs market in the U.S. is estimated at US$20.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$22.1 Billion by the year 2030 trailing a CAGR of 9.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 5.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global Metastatic Cancer Drugs Market - Key Trends & Drivers Summarized

Why Does Metastatic Cancer Demand Distinct Therapeutic Strategies Beyond Conventional Oncology Protocols?

Metastatic cancer, the stage at which malignancy spreads beyond its primary origin to distant organs, represents the most advanced and life-threatening phase of cancer progression. It remains one of the most difficult oncology challenges, accounting for the majority of cancer-related mortalities worldwide. Unlike localized tumors, metastatic cancers exhibit complex genetic heterogeneity, resistance to standard therapies, and reduced responsiveness to localized treatments like surgery and radiation-necessitating specialized pharmacologic approaches.

Treatment goals in metastatic settings often pivot from curative intent to prolonging survival, maintaining quality of life, and slowing disease progression. As such, drug development in this domain emphasizes cytostatic over cytotoxic effects, targeted inhibition of metastatic signaling pathways, and personalization based on molecular profiling. The growing recognition that metastasis represents a distinct biological state-rather than just a spatial extension-has spurred intensive research into its underlying mechanisms and therapeutics tailored for organ-specific metastases, such as brain, bone, or liver involvement.

How Are Targeted Therapies, Immuno-Oncology, and Genomic Innovations Reshaping the Drug Landscape?

The therapeutic landscape for metastatic cancer has evolved dramatically with the rise of targeted therapies, monoclonal antibodies, and immune checkpoint inhibitors. Drugs such as trastuzumab (HER2+ breast cancer), osimertinib (EGFR-mutant NSCLC), and enzalutamide (metastatic prostate cancer) exemplify how receptor-specific inhibition can extend survival in metastatic settings. These agents are designed to disrupt aberrant signaling cascades, inhibit angiogenesis, block hormone receptors, or interfere with metastatic cell migration and adhesion mechanisms.

Immunotherapies, especially PD-1/PD-L1 inhibitors like pembrolizumab and nivolumab, are revolutionizing outcomes in melanoma, NSCLC, and renal cell carcinoma by enhancing endogenous immune recognition of tumor cells. CAR-T cell therapies and bispecific antibodies are also being explored in metastatic hematologic and solid tumors, targeting persistent clones that evade first-line treatments. Genomic sequencing platforms and liquid biopsies enable real-time tracking of tumor mutations, helping match patients to precision therapies or combination regimens that target multiple metastatic drivers simultaneously.

Which Cancer Types and Regional Markets Are Driving Clinical and Commercial Expansion of Metastatic Oncology Drugs?

Breast, lung, colorectal, prostate, and melanoma represent the most commercially significant cancer types in the metastatic drug market, each with substantial patient populations and differentiated treatment pipelines. For instance, HER2-positive and triple-negative breast cancer have distinct metastatic progression patterns and corresponding therapies. Non-small cell lung cancer (NSCLC) with brain metastases is a high-priority area for next-generation ALK and EGFR inhibitors. Similarly, metastatic colorectal cancer (mCRC) and hepatocellular carcinoma are increasingly treated with biologics targeting VEGF, EGFR, or multikinase pathways.

North America and Europe remain the largest revenue-generating regions, supported by robust reimbursement structures, research infrastructure, and early access to FDA- and EMA-approved agents. However, Asia-Pacific markets-particularly China, Japan, and South Korea-are witnessing rapid growth due to increasing cancer prevalence, investments in biomarker-driven care, and the regional approval of biosimilars and homegrown immunotherapies. Latin America and the Middle East, though constrained by pricing and infrastructure gaps, are expanding access via public-private partnerships and cancer care reform initiatives.

What Is Driving Long-Term Growth and Innovation in the Metastatic Cancer Drug Market?

The growth in the metastatic cancer drugs market is being driven by rising cancer incidence, expanded molecular diagnostics, and strategic repositioning of novel therapeutics into late-stage treatment algorithms. Breakthroughs in cancer immunology, epigenetics, and tumor microenvironment modulation are expanding the scope of druggable targets. Companion diagnostics and biomarker-guided therapy selection are enabling better stratification of patients, improving response rates and minimizing trial-and-error in late-stage treatment.

Pharmaceutical pipelines are increasingly focused on combination regimens, sequencing strategies, and novel mechanisms such as antibody-drug conjugates (ADCs), PARP inhibitors, and tumor-agnostic therapies. Additionally, payer support for life-extending therapies in metastatic settings is enabling broader market access. Real-world evidence (RWE), value-based pricing models, and regulatory frameworks like accelerated approval and breakthrough therapy designation are further accelerating commercialization.

As metastatic cancer care moves toward increasingly individualized, biologically informed treatment regimens, the market for drugs addressing this high-mortality segment will continue to expand-underscoring the convergence of precision oncology, immune modulation, and translational research as core pillars of therapeutic advancement.

SCOPE OF STUDY:

The report analyzes the Metastatic Cancer Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Chemotherapy, Hormonal Therapy, Targeted Therapy, Immunotherapy); Indication (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Indications); Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Providers)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• AbbVie Inc.
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• Biogen Inc.
• Bristol-Myers Squibb Company
• Celgene Corporation
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Ipsen
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi S.A.
• Seagen Inc.
• Takeda Pharmaceutical Company

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Metastatic Cancer Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Surge in Late-Stage Cancer Diagnoses Drives Demand for Advanced Metastatic Cancer Therapies
  • Expansion of Immunotherapy and Targeted Therapies Throws the Spotlight on Drug Personalization
  • Rising Success of Checkpoint Inhibitors and PD-1/PD-L1 Blockers Propels New Product Pipelines
  • Development of Tumor-Agnostic Therapies Strengthens Business Case for Broad-Based Market Access
  • Increased Focus on Combination Therapies Enhances Efficacy in Resistant Metastatic Tumors
  • Growth in Companion Diagnostics and Genetic Profiling Expands Use of Precision Oncology Drugs
  • Integration of AI in Tumor Biology Research Accelerates Discovery of Novel Metastatic Pathways
  • Rapid Approvals of Orphan and Breakthrough Therapies Streamline Market Entry for High-Potential Drugs
  • Use of Liquid Biopsies for Treatment Monitoring Supports Adaptive Therapy Models
  • Collaborations Between Pharma and Diagnostic Companies Boost Development of Integrated Solutions
  • Expansion of Drug Access Programs in Low-Income Countries Strengthens Global Patient Reach
  • Clinical Trials Exploring Novel Antibody-Drug Conjugates Drive Expansion in Breast, Lung, and Colorectal Segments
  • Growth in Tumor Microenvironment Research Fuels Immunomodulatory Drug Development
  • Focus on Blood-Brain Barrier Penetration Enhances Drug Delivery for Brain Metastases
  • Use of Real-World Evidence and Digital Biomarkers Strengthens Post-Market Performance Tracking
  • Emergence of Multi-Target Inhibitors Enhances Treatment Options for Aggressive Metastatic Cancers
  • Shift Toward Value-Based Oncology Care Models Spurs Outcome-Centric Drug Pricing Strategies
  • Advancements in Nanomedicine and Smart Drug Delivery Systems Improve Target Specificity
  • Patient Advocacy and Accelerated FDA Pathways Drive Faster Commercialization of Late-Stage Therapies
  • Biopharma Investment in Pan-Cancer Drug Portfolios Expands Long-Term Strategic Market Presence
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Metastatic Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Metastatic Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Metastatic Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Drug Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Online Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 44: USA Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• JAPAN
  • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• CHINA
  • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 71: China Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• EUROPE
  • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Metastatic Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Metastatic Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• FRANCE
  • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 92: France Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 98: France Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: France 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• GERMANY
  • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Germany 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Italy 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 119: UK Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 125: UK Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: UK 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Spain 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Russia 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Metastatic Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Metastatic Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Australia 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• INDIA
  • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 176: India Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 182: India Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: India 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: South Korea 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Metastatic Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Metastatic Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Latin America 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Argentina 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Brazil 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Mexico 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Metastatic Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Metastatic Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Middle East 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Iran 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Israel 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: UAE 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• AFRICA
  • Metastatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Metastatic Cancer Drugs by Therapy - Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Metastatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Metastatic Cancer Drugs by Indication - Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Metastatic Cancer Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma for the Years 2015, 2025 & 2030
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Metastatic Cancer Drugs by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Africa 15-Year Perspective for Metastatic Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030

IV. COMPETITION